Elevated expression of tumor miR-222 in pancreatic cancer is associated with Ki67 and poor prognosis

Medical Oncology

Volumn 30, Issue 4, 2013, Pages

  Lee, Chonglek ^a   He, Hang ^a   Jiang, Yongjian ^a   Di, Yang ^a   Yang, Feng ^a   Li, Ji ^a   Jin, Chen ^a   Fu, Deliang ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Ki67; Micro RNA; miR 222; Pancreatic ductal adenocarcinoma (PDAC); Prognosis

Indexed keywords

KI 67 ANTIGEN; MICRORNA 222; TUMOR MARKER; MICRORNA; MIRN222 MICRORNA, HUMAN;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER TISSUE; CELL PROLIFERATION; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL TIME; GENETICS; MIDDLE AGED; PANCREAS TUMOR; PATHOLOGY; PROGNOSIS;

CELL PROLIFERATION; FEMALE; HUMANS; KI-67 ANTIGEN; MALE; MICRORNAS; MIDDLE AGED; PANCREATIC NEOPLASMS; PROGNOSIS; PROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 84883629897     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-013-0700-y     Document Type: Article

References (35)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012. doi: 10.3322/caac.20138.
2. Raimondi S, Maisonneuve P, Lowenfels AB. Epidemiology of pancreatic cancer: an overview. Nat Rev Gastroenterol Hepatol. 2009. doi: 10.1038/nrgastro.2009.177.
3. Hidalgo M. Pancreatic cancer. N Engl J Med. 2010. doi: 10.1056/NEJMra0901557.
4. Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet. 2011. doi: 10.1016/S0140-6736(10)62307-0.
5. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6(11):857-66. (Pubitemid 44629897)
6. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281-97. (Pubitemid 38167318)
7. Harfe BD. MicroRNAs in vertebrate development. Curr Opin Genet Dev. 2005;15(4):410-5. (Pubitemid 40982092)
8. Ambros V. The functions of animal microRNAs. Nature. 2004;431(7006):350- 5. (Pubitemid 39265675)
9. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 2006;6(4):259-69.
10. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR. MicroRNA expression profiles classify human cancers. Nature. 2005;435(7043):834-8. (Pubitemid 40839735)
11. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A,Negrini M, Harris CC, Croce CM. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci. 2006;103(7):2257-61. (Pubitemid 43271657)
12. le Sage C, Nagel R, Egan DA, Schrier M, Mesman E, Mangiola A, Anile C, Maira G, Mercatelli N, Ciafrè SA, Farace MG, Agami R. Regulation of the p27 (Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. EMBO J. 2007;26(15):3699-708. (Pubitemid 47236875)
13. Hwang MS, Yu N, Stinson SY, Yue P, Newman RJ, Allan BB, Dornan D. miR-221/222 Targets Adiponectin Receptor 1 to Promote the Epithelial-to- Mesenchymal Transition in Breast Cancer. PLoS One. 2013. doi: 10.1371/journal.pone.0066502.
14. Puerta-Gil P, García-Baquero R, Jia AY, Ocaña S, Alvarez-Múgica M, Alvarez-Ossorio JL, Cordon-Cardo C, Cava F, Sánchez-Carbayo M. miR-143, miR-222, and miR-452 are useful as tumor stratification and noninvasive diagnostic biomarkers for bladder cancer. Am J Pathol. 2012. doi: 10.1016/j.ajpath.2012.01.034.
15. Xu K, Liang X, Shen K, Sun L, Cui D, Zhao Y, Tian J, Ni L, Liu J. miR-222 modulates multidrug resistance in human colorectal carcinoma by down-regulating ADAM-17. Exp Cell Res. 2012. doi: 10.1016/j.yexcr.2012.04.014.
16. Quintavalle C, Garofalo M, Zanca C, Romano G, Iaboni M, del Basso De Caro M, Martinez-Montero JC, Incoronato M, Nuovo G, Croce CM, Condorelli G. miR-221/222 overexpression in human glioblastoma increases invasiveness by targeting the protein phosphate PTPμ. Oncogen. 2013. doi: 10.1038/onc.2011.280.
17. Huuhtanen RL, Blomqvist CP, Wiklund TA, Böhling TO, Virolainen MJ, Tukiainen EJ, Tribukait B, Andersson LC. Comparison of the Ki-67 score and S-phase fraction as prognostic variables in soft-tissue sarcoma. Br J Cancer. 1999;79(5-6):945-51. (Pubitemid 29082131)
18. Lee EJ, Gusev Y, Jiang J, Nuovo GJ, Lerner MR, Frankel WL, Morgan DL, Postier RG, Brackett DJ, Schmittgen TD. Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer. 2007;120(5):1046-54. (Pubitemid 46214304)
19. Szafranska AE, Davison TS, John J, Cannon T, Sipos B, Maghnouj A, Labourier E, Hahn SA. MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene. 2007;26(30):4442-52. (Pubitemid 47014466)
20. Bloomston M, Frankel WL, Petrocca F, Volinia S, Alder H, Hagan JP, Liu CG, Bhatt D, Taccioli C. Croce CM. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA. 2007;297(17):1901-8. (Pubitemid 46707844)
21. Papaconstantinou IG, Manta A, Gazouli M, Lyberopoulou A, Lykoudis PM, Polymeneas G, Voros D. Expression of microRNAs in patients with pancreatic cancer and its prognostic significance. Pancreas. 2013. doi: 10.1097/MPA.0b013e3182592ba7.
22. Yu J, Li A, Hong SM, Hruban RH, Goggins M. MicroRNA alterations of pancreatic intraepithelial neoplasias. Clin Cancer Res. 2012. doi: 10.1158/1078-0432.CCR-11-2347.
23. Zhang Y, Li M, Wang H, Fisher WE, Lin PH, Yao Q, Chen C. Profiling of 95 microRNAs in pancreatic cancer cell lines and surgical specimens by real-time PCR analysis. World J Surg. 2009. doi: 10.1007/s00268-008-9833-0.
24. Greither T, Grochola LF, Udelnow A, Lautenschläger C, Würl P, Taubert H. Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival. Int J Cancer. 2010. doi: 10.1002/ijc.24687.
25. Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer. 1983;31(1):13-20. (Pubitemid 13179545)
26. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000;182(3):311-22. (Pubitemid 30054364)
27. Bullwinkel J, Baron-Lühr B, Lüdemann A, Wohlenberg C, Gerdes J, Scholzen T. Ki-67 protein is associated with ribosomal RNA transcription in quiescent and proliferating cells. J Cell Physiol. 2006;206(3):624-35. (Pubitemid 43191037)
28. Rahmanzadeh R, Hüttmann G, Gerdes J, Scholzen T. Chromophore-assisted light inactivation of pKi-67 leads to inhibition of ribosomal RNA synthesis. Cell Prolif. 2007;40(3):422-30. (Pubitemid 46802182)
29. Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol. 2010. doi: 10.1016/S1470-2045(09)70262-1.
30. Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, Nielsen TO. Ki57 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst, 2009. doi: 10.1093/jnci/djp082.
31. Stanton KJ, Sidner RA, Miller GA, Cummings OW, Schmidt CM, Howard TJ, Wiebke EA. Analysis of Ki-67 antigen expression, DNA proliferative fraction, and survival in resected cancer of the pancreas. Am J Surg. 2003;186(5):486-92. (Pubitemid 37352833)
32. Medina R, Zaidi SK, Liu CG, Stein JL, van Wijnen AJ, Croce CM, Stein GS. MicroRNAs 221 and 222 bypass quiescence and compromise cell survival. Cancer Res. 2008. doi: 10.1158/0008-5472.CAN-07-6754. (Pubitemid 351556275)
33. Galardi S, Mercatelli N, Giorda E, Massalini S, Frajese GV, Ciafrè SA, Farace MG. miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1. J Biol Chem. 2007;282(32):23716-24. (Pubitemid 47311902)
34. Mercatelli N, Coppola V, Bonci D, Miele F, Costantini A, Guadagnoli M, Bonanno E, Muto G, Frajese GV, De Maria R, Spagnoli LG, Farace MG, Ciafrè SA. The inhibition of the highly expressed miR-221 and miR-222 impairs the growth of prostate carcinoma xenografts in mice. PLoS One. 2008. doi: 10.1371/journal.pone.0004029.
35. Visone R, Russo L, Pallante P, De Martino I, Ferraro A, Leone V, Borbone E, Petrocca F, Alder H, Croce CM, Fusco A. MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. Endocr Relat Cancer. 2007;14(3):791-8. (Pubitemid 350074067)